Markets
Intuitive Surgical (ISRG)
Leerink Partners analyst Richard Newitter maintained a Hold rating on Intuitive Surgical today and set a price target of $860.00. The company’s shares closed last Tuesday at $811.11, close to its 52-week high of $826.81.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of 27.9% and a 71.4% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Organogenesis Holdings.
Intuitive Surgical has an analyst consensus of Moderate Buy, with a price target consensus of $881.38, implying a 9.3% upside from current levels. In a report released today, Oppenheimer also upgraded the stock to Hold.
Edwards Lifesciences Corp (EW) Q1 2021 Earnings Call Transcript
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Abbott Laboratories Shares Slump as Q1 Earnings and Revenue Fall Shy of Expectations
fxempire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fxempire.com Daily Mail and Mail on Sunday newspapers.
The Globe and Mail Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Daily roundup of research and analysis from The Globe and Mail’s market strategist Scott Barlow
Michael Batnick, director of research for New York-based Ritholtz Wealth Management, warned investors against overconfidence in
It Gets Harder From Here,
“We’ve had bear markets before, but we’ve never had this type of rally in such a short period of time … If you feel like this is easy, check yourself. Do not get out over your skis. This has been a favorable environment for stocks and for raising money, and for cryptocurrencies of all shapes and sizes. So now is probably a good time to do some spring cleaning in your portfolio. I never advocate wholesale changes, but maybe trim some shrubs. In the unlikely e
Investor Newsletter
Sixteen ways to invest in the high-potential medical tech sector. Plus, why the TSX is set for an earnings bonanza Published April 19, 2021 Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Morgan Stanley analyst Cecilia Furlong’s earnings preview for the medical technology sector came in at an inbox-clogging 108 pages. I am already a convert to this sector having purchased a position in Stryker Corp. in November 2019.
If anything, the medical technology sector is even more attractive than in late 2019. Ms. Furlong notes that the sector is trading at less than a five per cent premium to the S&P 500 when a 30 per cent premium is the historical average, thanks to stable and high profit growth prospects.